The CD3-zeta chimeric antigen receptor overcomes TCR hypo-responsiveness of human terminal late-stage t cells

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Rappl, Gunter ^a   Riet, Tobias ^a   Awerkiew, Sabine ^a   Schmidt, Annette ^b   Hombach, Andreas A ^a   Pfister, Herbert ^a   Abken, Hinrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GALECTIN 3; SWAINSONINE; T LYMPHOCYTE RECEPTOR; CD3 ANTIGEN, ZETA CHAIN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN FUNCTION; ARTICLE; CD8+ T LYMPHOCYTE; CELL ANCHORAGE; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; EMBRYO; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTOTOXICITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPSE; ADULT; AGED; BLOOD; CELL CULTURE; CELL DIFFERENTIATION; CHEMISTRY; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD3; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSFECTION; YOUNG ADULT;

EID: 84856118995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030713     Document Type: Article

References (36)

1. Park TS, Rosenberg SA, Morgan RA, (2011) Treating cancer with genetically engineered T cells. Trends Biotechnol 29: 550-557.
2. Klebanoff CA, Acquavella N, Yu Z, Restifo NP, (2011) Therapeutic cancer vaccines: are we there yet? Immunol Rev 239: 27-44.
3. Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, et al. (2010) Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 28: 79-105.
4. Dustin ML, Chakraborty AK, Shaw AS, (2010) Understanding the structure and function of the immunological synapse. Cold Spring Harb Perspect Biol 2: a002311.
5. Garber K, (2011) Beyond ipilimumab: new approaches target the immunological synapse. J Natl Cancer Inst 103: 1079-1082.
6. Turtle CJ, Riddell SR, (2011) Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol 23: 299-305.
7. Rappl G, Schrama D, Hombach A, Meuer EK, Schmidt A, et al. (2008) CD7- T cells are late memory cells generated from CD7+ T cells. Rejuvenation Res 11: 543-556.
8. Simpson RJ, Cosgrove C, Chee MM, Mc Farlin BK, Bartlett DB, et al. (2010) Senescent phenotypes and telomere lengths of peripheral blood T cells mobilized by acute exercise in humans. Exerc Immunol Rev 16: 40-55.
9. Neeson P, Shin A, Tainton KM, Guru P, Prince HM, et al. (2010) Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Therapy 17: 1105-1116.
10. Larbi A, Pawelec G, Wong SC, Goldeck D, Tai JJ, et al. (2011) Impact of age on T cell signaling: a general defect or specific alterations? Ageing Res Rev 10: 370-378.
11. Vazquez-Cintron EJ, Monu NR, Frey AB, (2010) Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J Immunol 185: 7133-7140.
12. Ramos CA, Dotti G, (2011) Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 11: 855-873.
13. Roszik J, Sebestyen Z, Govers C, Guri Y, Szöör A, et al. (2011) T cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:zeta, a candidate transgene for TCR gene therapy. Eur J Immunol 41: 1288-1297.
14. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, et al. (2010) The optimal antigen response of chimeric antigen receptors harboring the CD3-zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 184: 6938-6949.
15. Hsu DK, Chen HY, Liu FT, (2009) Galectin-3 regulates T cell functions. Immunol Rev 230: 114-127.
16. Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA, (2006) Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177: 6527-6539.
17. Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein B, (2011) Gain and loss of T cell subsets in old age-age-related reshaping of the T cell repertoire. J Clin Immunol 31: 137-146.
18. Buchholz VR, Neuenhahn M, Busch DH, (2011) CD8+ T cell differentiation in the aging immune system: until the last clone standing. Curr Opin Immunol 23: 549-554.
19. Boding L, Bonefeld CM, Nielsen BL, Lauritsen JPH, von Essen MR, et al. (2009) TCR down-regulation controls T cell homeostasis. J Immunol 183: 4994-5005.
20. Chen HY, Fermin A, Vardhana S, Weng IC, Lo KFR, et al. (2009) Galectin-3 negatively regulates TCR-mediated CD4+ T cell activation at the immunological synapse. Proc Natl Acad Sci 106: 14496-14501.
21. Demotte N, Wieërs G, van der Smissen P, Moser M, Schmidt C, et al. (2010) A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 70: 7476-7488.
22. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, et al. (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176: 778-789.
23. Grigorian A, Demetriou M, (2010) Manipulating cell surface glycoproteins by targeting N-glycan-galectin interactions. Methods Enzymol 480: 245-266.
24. Linnemann C, Schumacher TN, Bendle GM, (2011) T cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol 131: 1806-1816.
25. Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TN, (2011) Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther 11: 276-287.
26. Bartelt RR, Cruz-Orcutt N, Collins M, Houtman JCD, (2009) Comparison of T cell receptor-induced proximal signaling and downstream functions in immortalized and primary T cells. PLoS ONE 4: e5430.
27. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, et al. (2009) Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 69: 8412-8419.
28. Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, et al. (2011) Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE 6: e20466.
29. Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, et al. (2005) Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat Immunol 6: 889-894.
30. Weiner HL, da Cunha AP, Quintana F, Wu H, (2011) Oral tolerance. Immunol Rev 241: 241-259.
31. Ohno-Iwashita Y, Shimada Y, Hayashi M, Inomata M, (2010) Plasma membrane microdomains in aging and disease. Geriatr Gerontol Int 10 (Suppl 1): S41-52.
32. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, et al. (2011) Intrinsic and extrinsic control of peripheral T cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev 241: 180-205.
33. Effros RB, (2011) Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress. Exp Gerontol 46: 135-140.
34. Hombach A, Heuser C, Abken H, (2003) Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy. Methods Mol Biol 207: 365-381.
35. Kaulen H, Seemann G, Bosslet K, Schwaeble W, Dippold W, (1993) Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. Year Immunol 7: 106-109.
36. Tavano R, Contento RL, Baranda SJ, Soligo M, Tosto L, et al. (2006) CD28 interaction with filamin-A controls lipid raft accumulation at the T cell immunological synapse. Nature Cell Biology 8: 1270-1276.